December 2014

New Product - Jardiance

Jardiance (empagliflozin) is a reversible competitive inhibitor of SGLT2 (IC50 of 1.3 nM) and has a 5000-fold selectivity over human SGLT1 (IC50 of 6278 nM), responsible for glucose absorption in the gut. Jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; and as add-on combination therapy in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Jardiance is contraindicated in patients with chronic kidney disease stage 4 or 5 (severely impaired renal function including patients receiving dialysis). Jardiance is available as 10 mg and 25 mg tablets in packs of 30’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629